Form: 8-K

Current report filing

October 27, 2014

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 22, 2014

 

 

NEOGENOMICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Nevada   001-35756   74-2897368

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

12701 Commonwealth Drive, Suite 9, Fort Myers,

Florida

  33913
(Address of principal executive offices)   (Zip Code)

(239) 768-0600

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 22, 2014, the board of directors (the “Board”) of NeoGenomics, Inc. (the “Company”) appointed Bruce Crowther to serve as a member of the Board effective immediately, filling a vacancy created by an increase in the size of the Board from six to seven. It is expected that Mr. Crowther will serve on the Board’s audit committee and compliance committee. Mr. Crowther will receive quarterly fees of $11,250 paid quarterly in arrears for his service on the board of directors. Mr. Crowther will also receive fees for his service on the audit committee and on the compliance committee. Those fees will be $1,250 per committee per quarter and will be paid quarterly in arrears. Mr. Crowther will also receive a restricted stock grant of 1,500 shares which will vest over the next two (2) quarters for his service on the board of directors.

 

Item 9.01. Financial Statements and Exhibits.

 

  (a) Not applicable

 

  (b) Not applicable

 

  (c) Not applicable

 

  (d) Exhibits.

 

EXHIBIT

  

DESCRIPTION

  

LOCATION

     
     
     

 

- 2 -


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  NEOGENOMICS, INC.
By:  

/s/ George Cardoza

  George Cardoza
  Chief Financial Officer

Date: October 27, 2014

 

- 3 -


Exhibit Index

 

Exhibit
No.

  

Description

  
  
  

 

- 4 -